Theralase Technologies (CVE:TLT) Trading Down 12.3% – What’s Next?
by Sarita Garza · The Markets DailyShares of Theralase Technologies Inc. (CVE:TLT – Get Free Report) were down 12.3% during trading on Tuesday . The company traded as low as C$0.25 and last traded at C$0.25. Approximately 225,401 shares were traded during trading, a decline of 55% from the average daily volume of 495,644 shares. The stock had previously closed at C$0.29.
Theralase Technologies Stock Performance
The firm’s 50-day moving average price is C$0.18 and its two-hundred day moving average price is C$0.19. The company has a quick ratio of 3.40, a current ratio of 1.91 and a debt-to-equity ratio of 14.85. The firm has a market capitalization of C$67.55 million, a PE ratio of -14.17 and a beta of -0.35.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.